AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25053749 — intervention group
Group type: EXPERIMENTAL
Intervention: FroDex25 (frovatriptan 2.5 mg + dexketoprofen 25 mg)
Number of subjects: 76
Study 23566639 — intervention group
Group type: EXPERIMENTAL
Intervention: P/MC (sodium picosulfate and magnesium citrate)
Number of subjects: 601
Study 23566639 — intervention group
Group type: COMPARATOR
Intervention: 2L PEG‐3350 and bisacodyl tablets
Number of subjects: 601
Study 21447908 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training program twice a week for 6 weeks
Number of subjects: 28
Study 21447908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study 19428097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS)
Number of subjects: 20
Study 19428097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16455424 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional echocardiography (3DE)
Number of subjects: 30
Study 16455424 — intervention group
Group type: EXPERIMENTAL
Intervention: TI-201 single photon emission computed tomography (SPECT)
Number of subjects: 30
Study 15381675 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (66 microg/kg per min for 30 minutes)
Number of subjects: 10
Study 15381675 — intervention group
Group type: COMPARATOR
Intervention: L-arginine (3 g TID) plus ramipril (10 mg QD)
Number of subjects: 10
Study 15381675 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME
Number of subjects: 10
Study 15381675 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 10
Study 11528242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 40 mg of iron during the first ten HD sessions (n = 12)
Number of subjects: 35
Study 11528242 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injection of 40 mg of iron for 10 weeks (n = 12)
Number of subjects: 35
Study 11528242 — intervention group
Group type: COMPARATOR
Intervention: No iron supplementation (n = 11)
Number of subjects: 35
Study 9623154 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of sodium cromoglycate through a spacer device
Number of subjects: 218
Study 9623154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 7940732 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3-based immunoprophylaxis with steroids and azathioprine for 14 days, cyclosporine introduced on day 11 posttransplant.
Number of subjects: 96
Study 7940732 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine-based immunoprophylaxis with steroids and azathioprine.
Number of subjects: 96
Study 3349748 — intervention group
Group type: EXPERIMENTAL
Intervention: Procan SR 1 g
Number of subjects: 10
Study 3349748 — intervention group
Group type: COMPARATOR
Intervention: Pronestyl-SR 1 g
Number of subjects: 10
Study 3349748 — intervention group
Group type: EXPERIMENTAL
Intervention: Procan SR and Pronestyl-SR
Number of subjects: 10
Study 30910541 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan plus melphalan
Number of subjects: 202
Study 30910541 — intervention group
Group type: COMPARATOR
Intervention: Melphalan alone
Number of subjects: 202
Study 28801399 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical care plus computer-based screening and personalised assessment feedback
Number of subjects: 44
Study 28801399 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus computer-based sham
Number of subjects: 44
Study 28801399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 25743733 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care with an aroma solution
Number of subjects: 61
Study 25743733 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (Control)
Number of subjects: 61
Study 23786836 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI>30 kg/m2)
Number of subjects: 730
Study 23786836 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients (25<BMI<30 kg/m2)
Number of subjects: 730
Study 23786836 — intervention group
Group type: COMPARATOR
Intervention: Patients with BMI<25 kg/m2
Number of subjects: 730
Study 23786836 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 730
Study 23786836 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese and overweight patients
Number of subjects: 730
Study 22131238 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 50
Study 22131238 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydralazine
Number of subjects: 50
Study 19288431 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer of a social counselling service
Number of subjects: 223
Study 19288431 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer of a work-related stress coping training
Number of subjects: 223
Study 19288431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of therapy increased from 3 to 5 hours
Number of subjects: 223
Study 19288431 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced waiting time
Number of subjects: 223
Study 17323586 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 0
Study 17323586 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg
Number of subjects: 0
Study 15565999 — intervention group
Group type: EXPERIMENTAL
Intervention: BID group (0.5 g morning and evening)
Number of subjects: 55
Study 15565999 — intervention group
Group type: EXPERIMENTAL
Intervention: TID group (0.25 g in the morning and about midday, and 0.5 g in the evening)
Number of subjects: 55
Study 11203833 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose (SBMP) with pre-cure technique
Number of subjects: 90
Study 11203833 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond (CFLB) with pre-cure technique
Number of subjects: 90
Study 11203833 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond One‐Step (SB1S) with pre-cure technique
Number of subjects: 90
Study 11203833 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Fuji Bond LC with co-cure technique
Number of subjects: 90
Study 11203833 — intervention group
Group type: EXPERIMENTAL
Intervention: CFLB with co-cure technique
Number of subjects: 90
Study 11203833 — intervention group
Group type: EXPERIMENTAL
Intervention: CFLB with pre-cure technique
Number of subjects: 90
Study 11203833 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose, Scotchbond One‐Step, Fuji Bond LC with co-cure technique
Number of subjects: 90
Study 11203833 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond with pre-cure technique
Number of subjects: 90
Study 11203833 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no dentin bonding)
Number of subjects: 90
Study 9093207 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate plus T undecanoate
Number of subjects: 80
Study 9093207 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen citrate
Number of subjects: 80
Study 9093207 — intervention group
Group type: COMPARATOR
Intervention: T undecanoate
Number of subjects: 80
Study 9093207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9093207 — intervention group
Group type: EXPERIMENTAL
Intervention: T undecanoate plus tamoxifen citrate
Number of subjects: 80
Study 1389661 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol with NaCl (28 mmol/l)
Number of subjects: 75
Study 1389661 — intervention group
Group type: COMPARATOR
Intervention: iohexol without NaCl
Number of subjects: 75
Study 3877280 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 3877280 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 60
Study 30397257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling biannually from age 7 months to 20 years
Number of subjects: 1062
Study 30098162 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical or surgical treatment of the study eye (SE)
Number of subjects: 607
Study 26409751 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 104
Study 26409751 — intervention group
Group type: COMPARATOR
Intervention: Counseling without buprenorphine
Number of subjects: 104
Study 23736314 — intervention group
Group type: COMPARATOR
Intervention: 0 mg oral naltrexone (NTX)
Number of subjects: 12
Study 23736314 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg oral naltrexone (NTX)
Number of subjects: 12
Study 23736314 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral naltrexone (NTX)
Number of subjects: 12
Study 23736314 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral D-amphetamine (D-AMPH)
Number of subjects: 12
Study 23736314 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral D-amphetamine (D-AMPH)
Number of subjects: 12
Study 23736314 — intervention group
Group type: COMPARATOR
Intervention: 0 mg smoked cocaine (COC)
Number of subjects: 12
Study 23736314 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg smoked cocaine (COC)
Number of subjects: 12
Study 23736314 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg smoked cocaine (COC)
Number of subjects: 12
Study 23736314 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg smoked cocaine (COC)
Number of subjects: 12
Study 21871685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (Group A)
Number of subjects: 42
Study 21871685 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (Group B)
Number of subjects: 42
Study 18978638 — intervention group
Group type: EXPERIMENTAL
Intervention: ERr 731
Number of subjects: 109
Study 18978638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially) then ERr 731
Number of subjects: 109
Study 18978638 — intervention group
Group type: EXPERIMENTAL
Intervention: All women (ERr 731 and placebo)
Number of subjects: 109
Study 17098309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous boluses of quinaprilat
Number of subjects: 23
Study 17098309 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of sodium nitroprusside
Number of subjects: 23
Study 15184205 — intervention group
Group type: EXPERIMENTAL
Intervention: PEF plus symptom‐based management
Number of subjects: 90
Study 15184205 — intervention group
Group type: COMPARATOR
Intervention: Symptom‐based management alone
Number of subjects: 90
Study 11578760 — intervention group
Group type: EXPERIMENTAL
Intervention: D002 (50 mg/day)
Number of subjects: 50
Study 11578760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9821900 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating current at 1kHz
Number of subjects: 15
Study 9821900 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating current at increasing frequencies (2kHz to 15kHz)
Number of subjects: 15
Study 9821900 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating current at varying stimulus intensity
Number of subjects: 15
Study 9821900 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating current at 10kHz
Number of subjects: 15
Study 9821900 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating current at 1kHz or less
Number of subjects: 15
Study 10384427 — intervention group
Group type: EXPERIMENTAL
Intervention: Java-based data collection system
Number of subjects: 0
Study 10384427 — intervention group
Group type: COMPARATOR
Intervention: HTML/CGI approach
Number of subjects: 0
Study 1859509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 60 mg amitriptylinoxide
Number of subjects: 12
Study 1859509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 60 mg amitriptylinoxide
Number of subjects: 12
Study 1859509 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine analysis for metabolites
Number of subjects: 12
Study 1859509 — intervention group
Group type: COMPARATOR
Intervention: Overall tolerability of both preparations
Number of subjects: 12
Study 6135365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving encouragement to lower alcohol consumption and GGT measurements as biofeedback.
Number of subjects: 585
Study 6135365 — intervention group
Group type: COMPARATOR
Intervention: Control group informed to be restrictive with alcohol consumption and receive new invitations for liver enzyme measurements.
Number of subjects: 585
Study 30130424 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Seconds to Survival© (60S), a disaster triage screen-based simulation (SBS)
Number of subjects: 39
Study 30130424 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to 60S)
Number of subjects: 39
Study 30130424 — intervention group
Group type: COMPARATOR
Intervention: Previous immersive simulation study
Number of subjects: 39
Study 29608793 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-handed (FH) surgery
Number of subjects: 32
Study 29608793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot-drill guided (PG) surgery
Number of subjects: 32
Study 29608793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully guided (FG) surgery
Number of subjects: 32
Study 26095052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound arm (annual transvaginal ultrasound examinations)
Number of subjects: 48230
Study 26095052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographers (78 included in the model)
Number of subjects: 48230
Study 26095052 — intervention group
Group type: EXPERIMENTAL
Intervention: Centers (13 centers included)
Number of subjects: 48230
Study 26095052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographers over time
Number of subjects: 48230
Study 26095052 — intervention group
Group type: EXPERIMENTAL
Intervention: Centers over time
Number of subjects: 48230
Study 24225379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortolone (FC) 1 mg/kg for 5 days, followed by stepwise dose reduction
Number of subjects: 60
Study 24225379 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (PFX) intravenously and per os for 7 days, then per os for 6 months
Number of subjects: 60
Study 24225379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortolone (FC) for patients with baseline BCVA >=0.05
Number of subjects: 60
Study 24225379 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (PFX)
Number of subjects: 60
Study 24225379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortolone (FC)
Number of subjects: 60
Study 21952668 — intervention group
Group type: COMPARATOR
Intervention: MDMA 0 mg (placebo)
Number of subjects: 16
Study 21952668 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 25 mg
Number of subjects: 16
Study 21952668 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 50 mg
Number of subjects: 16
Study 21952668 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 100 mg
Number of subjects: 16
Study 20651093 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory stimuli (warming and cooling temperature, pain, touch, two-point discrimination) applied to the upper lip and chin
Number of subjects: 178
Study 20651093 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste stimuli
Number of subjects: 178
Study 20651093 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory stimuli
Number of subjects: 178
Study 18928339 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (2-15 mg/day)
Number of subjects: 0
Study 18928339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15972695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 15972695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12432317 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (within 24 hours of injury)
Number of subjects: 77
Study 12432317 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral feeding (at least 48 hours postburn)
Number of subjects: 77
Study 9534648 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-chosen music
Number of subjects: 12
Study 9534648 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 12
Study 9534648 — intervention group
Group type: COMPARATOR
Intervention: White noise
Number of subjects: 12
Study 9534648 — intervention group
Group type: COMPARATOR
Intervention: Classical music
Number of subjects: 12
Study 9480136 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent-inactivated plasma (SDP-TNBT/Triton X-100)
Number of subjects: 14
Study 9480136 — intervention group
Group type: COMPARATOR
Intervention: Untreated fresh-frozen plasma (FFP)
Number of subjects: 14
Study 3140150 — intervention group
Group type: EXPERIMENTAL
Intervention: Veralipride (100 mg/day for 30 days)
Number of subjects: 20
Study 3140150 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion (N = 5) after Veralipride administration
Number of subjects: 20
Study 3140150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4826687 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a bicycle ergometer for 10 weeks
Number of subjects: 44
Study 4826687 — intervention group
Group type: COMPARATOR
Intervention: 5 weeks of detraining
Number of subjects: 44
Study 4826687 — intervention group
Group type: COMPARATOR
Intervention: 10 weeks of detraining
Number of subjects: 44
Study 29893223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Number of subjects: 348
Study 29893223 — intervention group
Group type: COMPARATOR
Intervention: Personalised hip therapy
Number of subjects: 348
Study 28814431 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin
Number of subjects: 215
Study 28814431 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin after 12 months of treatment
Number of subjects: 215
Study 28814431 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of calprotectin, ESR, and CRP
Number of subjects: 215
Study 28814431 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of calprotectin
Number of subjects: 215
Study 24566599 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftaroline fosamil
Number of subjects: 614
Study 24566599 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone
Number of subjects: 614
Study 23182993 — intervention group
Group type: COMPARATOR
Intervention: Induction cisplatin/fluorouracil (PF) followed by RT
Number of subjects: 520
Study 23182993 — intervention group
Group type: COMPARATOR
Intervention: Concomitant cisplatin/RT
Number of subjects: 520
Study 20569725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg intravenous infusion for 10 minutes, followed by 2 mg/kg if needed)
Number of subjects: 236
Study 20569725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 236
Study 17996926 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiotherapy (PRT)
Number of subjects: 385
Study 17996926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide‐doxorubicin‐cisplatin (CAP) chemotherapy
Number of subjects: 385
Study 16885205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy
Number of subjects: 85
Study 12657584 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs) with a +2.00 addition (n = 235)
Number of subjects: 469
Study 12657584 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses (SVLs) (n = 234)
Number of subjects: 469
Study 10826516 — intervention group
Group type: EXPERIMENTAL
Intervention: NN304 [0.3 U/kg]
Number of subjects: 10
Study 10826516 — intervention group
Group type: EXPERIMENTAL
Intervention: NN304 [0.6 U/kg]
Number of subjects: 10
Study 10826516 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH [0.3 IU/kg]
Number of subjects: 10
Study 10826516 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH [0.6 IU/kg]
Number of subjects: 10
Study 8640969 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma brain natriuretic peptide (BNP)
Number of subjects: 131
Study 8640969 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma atrial natriuretic peptide (ANP)
Number of subjects: 131
Study 8640969 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal proatrial natriuretic peptide (N-ANP)
Number of subjects: 131
Study 8640969 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 131
Study 1383819 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 325
Study 1383819 — intervention group
Group type: COMPARATOR
Intervention: m-BACOD regimen (bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin)
Number of subjects: 325
Study 1383819 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Number of subjects: 325
Study 4054701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg tds with meals
Number of subjects: 246
Study 4054701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg at bedtime
Number of subjects: 246
Study 4054701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg tds with meals plus 400 mg at bedtime
Number of subjects: 246
Study 4054701 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (not specified)
Number of subjects: 246
Study 30114193 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking care outside the home
Number of subjects: 1103
Study 30114193 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antibiotics
Number of subjects: 1103
Study 30114193 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical insurance reimbursement
Number of subjects: 1103
Study 30114193 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender influence on care-seeking
Number of subjects: 1103
Study 30114193 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms influence on antibiotic use
Number of subjects: 1103
Study 30114193 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of hospital visited
Number of subjects: 1103
Study 30114193 — intervention group
Group type: EXPERIMENTAL
Intervention: Income influence on antibiotic receipt
Number of subjects: 1103
Study 30114193 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of antibiotic use
Number of subjects: 1103
Study 26614273 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Number of subjects: 14
Study 26614273 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 14